Diallo, K.; Degboé, Y.; Baron, M.; Bellin-Robert, A.; Boyer, J.-F.; Ruyssen-Witrand, A.; Constantin, A.; Rauwel, B.; Cantagrel, A.; Davignon, J.-L.
Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. Diagnostics 2025, 15, 1232.
https://doi.org/10.3390/diagnostics15101232
AMA Style
Diallo K, Degboé Y, Baron M, Bellin-Robert A, Boyer J-F, Ruyssen-Witrand A, Constantin A, Rauwel B, Cantagrel A, Davignon J-L.
Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. Diagnostics. 2025; 15(10):1232.
https://doi.org/10.3390/diagnostics15101232
Chicago/Turabian Style
Diallo, Katy, Yannick Degboé, Michel Baron, Anaïs Bellin-Robert, Jean-Frédéric Boyer, Adeline Ruyssen-Witrand, Arnaud Constantin, Benjamin Rauwel, Alain Cantagrel, and Jean-Luc Davignon.
2025. "Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation" Diagnostics 15, no. 10: 1232.
https://doi.org/10.3390/diagnostics15101232
APA Style
Diallo, K., Degboé, Y., Baron, M., Bellin-Robert, A., Boyer, J.-F., Ruyssen-Witrand, A., Constantin, A., Rauwel, B., Cantagrel, A., & Davignon, J.-L.
(2025). Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. Diagnostics, 15(10), 1232.
https://doi.org/10.3390/diagnostics15101232
